| Patient | Georgia O'Keeffe |
|---|---|
| Date of birth | 1945-11-15 |
| Identifiers | MRN HR-ET011-SYN; SSN (made up) 000-11-5873 |
| Document date | 2026-11-01 |
| Author | Wendell Ashby, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Primary care visit for new wavy lines and a blurred spot in the left eye. Concerns: Afraid of losing the central vision she needs to paint; Wants to keep living alone and driving to her studio. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Amsler grid assessment, both eyes | 2026-03-10 to 2026-03-10 | completed | S |
| Optical coherence tomography of the macula, both eyes | 2026-03-12 to 2026-03-12 | completed | S |
| Intravitreal injection of aflibercept 2 mg, left eye (injection 1) | 2026-03-12 to 2026-03-12 | completed | S |
| Optical coherence tomography of the macula, left eye | 2026-04-09 to 2026-04-09 | completed | S |
| Intravitreal injection of aflibercept 2 mg, left eye (injection 2) | 2026-04-09 to 2026-04-09 | completed | S |
| Optical coherence tomography of the macula, left eye | 2026-05-07 to 2026-05-07 | completed | S |
| Intravitreal injection of aflibercept 2 mg, left eye (injection 3) | 2026-05-07 to 2026-05-07 | completed | S |
| Optical coherence tomography of the macula, both eyes | 2026-07-02 to 2026-07-02 | completed | S |
| Intravitreal injection of aflibercept 2 mg, left eye (injection 4) | 2026-07-02 to 2026-07-02 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2025-10-15 | High-dose influenza vaccine, 2025-2026 season | completed | S |
| 2026-03-10 | Recombinant zoster vaccine, dose 1 | completed | S |
| 2026-10-15 | High-dose influenza vaccine, 2026-2027 season | completed | S |
| 2026-10-15 | Recombinant zoster vaccine, dose 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1927 | Two operations for benign breast cysts at Mount Sinai Hospital in 1927 | D (CLM-0004) |
| February 1933 | Hospitalized in February 1933 with psychoneurosis; recuperated in Bermuda | D (CLM-0005) |
| 1968 | Eyesight began to fail in 1968 | D (CLM-0006) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| mother | Died in May 1916; cause not recorded in the cited source | D (CLM-0003) | |
| father | Died in November 1918; cause not recorded in the cited source | D (CLM-0003) |
| Concern | Status | Evidence |
|---|---|---|
| Afraid of losing the central vision she needs to paint | active | S |
| Wants to keep living alone and driving to her studio | active | S |
Most recent measures: Visual acuity best corrected Right eye by ETDRS eye chart 77 on 2026-07-02; Visual acuity best corrected Left eye by ETDRS eye chart 70 on 2026-07-02; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-10-15; Total score [Mini-Cog] 5 on 2026-10-15; Macular grid.center subfield thickness by OCT 268 on 2026-07-02; Right eye Intraocular pressure 15 on 2026-07-02; Left eye Intraocular pressure 15 on 2026-07-02; Total score [AUDIT-C] 0 on 2026-10-15 [S]
Strengths and supports: Supports: a studio assistant, a housekeeper, and a sister who calls weekly; drives only short distances by day [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Neovascular (wet) age-related macular degeneration, left eye, with active choroidal neovascularization | active | confirmed | H35.3221 | S — Synthetic modern diagnosis linked to her documented failing eyesight; the historical type of macular degeneration is not recorded. |
| Nonexudative age-related macular degeneration, right eye, intermediate stage | active | confirmed | H35.3112 | S — Synthetic finding in the fellow eye. |
| Lateral sprain of the left ankle after a trip on uneven ground in low morning light, resolved | resolved | confirmed | S93.492A | S — Synthetic intercurrent injury at an unscheduled visit; it does not echo a documented injury. |
| New distortion (wavy lines) and a blurred central spot with reduced acuity in the left eye; suspected neovascular macular degeneration, urgent retina referral | resolved | confirmed | H53.15 | S — Synthetic presenting concern at the index visit, superseded by the OCT diagnosis at the retina consultation; her failing eyesight is documented (D). |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-10 | Visual acuity best corrected Right eye by ETDRS eye chart | 78 | {letters} | >=80 | Low | S |
| 2026-03-10 | Visual acuity best corrected Left eye by ETDRS eye chart | 56 | {letters} | >=80 | Low | S |
| 2026-03-10 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-03-10 | Total score [Mini-Cog] | 5 | {score} | S | ||
| 2026-03-12 | Visual acuity best corrected Right eye by ETDRS eye chart | 78 | {letters} | >=80 | Low | S |
| 2026-03-12 | Visual acuity best corrected Left eye by ETDRS eye chart | 55 | {letters} | >=80 | Low | S |
| 2026-03-12 | Macular grid.center subfield thickness by OCT | 418 | um | 200-300 um | High | S |
| 2026-03-12 | Right eye Intraocular pressure | 15 | mm[Hg] | 10-21 mmHg | Normal | S |
| 2026-03-12 | Left eye Intraocular pressure | 16 | mm[Hg] | 10-21 mmHg | Normal | S |
| 2026-04-09 | Visual acuity best corrected Left eye by ETDRS eye chart | 64 | {letters} | >=80 | Low | S |
| 2026-04-09 | Macular grid.center subfield thickness by OCT | 322 | um | 200-300 um | High | S |
| 2026-04-09 | Left eye Intraocular pressure | 15 | mm[Hg] | 10-21 mmHg | Normal | S |
| 2026-05-07 | Visual acuity best corrected Left eye by ETDRS eye chart | 69 | {letters} | >=80 | Low | S |
| 2026-05-07 | Macular grid.center subfield thickness by OCT | 274 | um | 200-300 um | Normal | S |
| 2026-05-07 | Left eye Intraocular pressure | 14 | mm[Hg] | 10-21 mmHg | Normal | S |
| 2026-07-02 | Visual acuity best corrected Right eye by ETDRS eye chart | 77 | {letters} | >=80 | Low | S |
| 2026-07-02 | Visual acuity best corrected Left eye by ETDRS eye chart | 70 | {letters} | >=80 | Low | S |
| 2026-07-02 | Macular grid.center subfield thickness by OCT | 268 | um | 200-300 um | Normal | S |
| 2026-07-02 | Right eye Intraocular pressure | 15 | mm[Hg] | 10-21 mmHg | Normal | S |
| 2026-07-02 | Left eye Intraocular pressure | 15 | mm[Hg] | 10-21 mmHg | Normal | S |
| 2026-07-02 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-10-15 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-10-15 | Total score [Mini-Cog] | 5 | {score} | S | ||
| 2026-10-15 | Total score [AUDIT-C] | 0 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-10 | Body height | 165 | cm | S |
| 2026-03-10 | Body weight | 56 | kg | S |
| 2026-03-10 | Body mass index (BMI) [Ratio] | 20.6 | kg/m2 | S |
| 2026-03-10 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-03-10 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-03-10 | Heart rate | 70 | /min | S |
| 2026-03-10 | Respiratory rate | 14 | /min | S |
| 2026-03-10 | Body temperature | 36.6 | Cel | S |
| 2026-03-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-03-12 | Body height | 165 | cm | S |
| 2026-03-12 | Body weight | 56 | kg | S |
| 2026-03-12 | Body mass index (BMI) [Ratio] | 20.6 | kg/m2 | S |
| 2026-03-12 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2026-03-12 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-03-12 | Heart rate | 72 | /min | S |
| 2026-03-12 | Respiratory rate | 14 | /min | S |
| 2026-03-12 | Body temperature | 36.5 | Cel | S |
| 2026-03-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-04-09 | Body height | 165 | cm | S |
| 2026-04-09 | Body weight | 55.5 | kg | S |
| 2026-04-09 | Body mass index (BMI) [Ratio] | 20.4 | kg/m2 | S |
| 2026-04-09 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-04-09 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-04-09 | Heart rate | 68 | /min | S |
| 2026-04-09 | Respiratory rate | 14 | /min | S |
| 2026-04-09 | Body temperature | 36.6 | Cel | S |
| 2026-04-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-05-07 | Body height | 165 | cm | S |
| 2026-05-07 | Body weight | 56 | kg | S |
| 2026-05-07 | Body mass index (BMI) [Ratio] | 20.6 | kg/m2 | S |
| 2026-05-07 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-05-07 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-05-07 | Heart rate | 68 | /min | S |
| 2026-05-07 | Respiratory rate | 14 | /min | S |
| 2026-05-07 | Body temperature | 36.6 | Cel | S |
| 2026-05-07 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-07-02 | Body height | 165 | cm | S |
| 2026-07-02 | Body weight | 56.5 | kg | S |
| 2026-07-02 | Body mass index (BMI) [Ratio] | 20.8 | kg/m2 | S |
| 2026-07-02 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-07-02 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-07-02 | Heart rate | 70 | /min | S |
| 2026-07-02 | Respiratory rate | 14 | /min | S |
| 2026-07-02 | Body temperature | 36.7 | Cel | S |
| 2026-07-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-08-20 | Body height | 165 | cm | S |
| 2026-08-20 | Body weight | 56.4 | kg | S |
| 2026-08-20 | Body mass index (BMI) [Ratio] | 20.7 | kg/m2 | S |
| 2026-08-20 | Systolic blood pressure | 136 | mm[Hg] | S |
| 2026-08-20 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-08-20 | Heart rate | 76 | /min | S |
| 2026-08-20 | Respiratory rate | 14 | /min | S |
| 2026-08-20 | Body temperature | 36.6 | Cel | S |
| 2026-08-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-10-15 | Body height | 165 | cm | S |
| 2026-10-15 | Body weight | 56.2 | kg | S |
| 2026-10-15 | Body mass index (BMI) [Ratio] | 20.6 | kg/m2 | S |
| 2026-10-15 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-10-15 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-10-15 | Heart rate | 68 | /min | S |
| 2026-10-15 | Respiratory rate | 14 | /min | S |
| 2026-10-15 | Body temperature | 36.5 | Cel | S |
| 2026-10-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-03-10 | Primary care visit for new wavy lines and a blurred spot in the left eye | finished | S |
| 2026-03-12 | Ophthalmology consultation, retinal imaging, and first anti-VEGF injection | finished | S |
| 2026-04-09 | Four-week retina follow-up with OCT and second injection | finished | S |
| 2026-05-07 | Eight-week retina follow-up with OCT and third injection | finished | S |
| 2026-07-02 | Treat-and-extend retina visit and primary care review of vision rehabilitation | finished | S |
| 2026-08-20 | Same-day sick visit for a left ankle sprain after a fall | finished | S |
| 2026-10-15 | Subsequent annual wellness visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Same-week ophthalmology consultation for new distortion and reduced acuity in the left eye, with OCT and fluorescein or OCT angiography as needed | completed | GL-AAO-AMD-2024 | S |
| Intravitreal aflibercept 2 mg in the left eye every four weeks for three doses, then treat-and-extend by two-week steps while the macula stays dry | completed | GL-AAO-AMD-2024 | S |
| At each injection visit: best-corrected acuity, OCT, and intraocular pressure before and after injection; teach warning signs of endophthalmitis and retinal detachment | completed | GL-AAO-AMD-2024, GL-CMID-2026 | S |
| Start an AREDS2 supplement (vitamin C 500 mg, vitamin E 400 IU, lutein 10 mg, zeaxanthin 2 mg, zinc 80 mg, copper 2 mg daily) for intermediate AMD in the right eye; no beta-carotene | completed | GL-AAO-AMD-2024 | S |
| Daily home Amsler grid checks for each eye, with same-day calls for new distortion; dilated examination of the right eye at each retina visit | completed | GL-AAO-AMD-2024 | S |
| Low-vision rehabilitation: task lighting, magnification, high-contrast marking, home fall-risk review, and a driving assessment | completed | GL-AAO-AMD-2024, GL-CMID-2026 | S |
| Repeat the PHQ-2 at follow-up because vision loss raises the risk of depression | completed | GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Gain at least 10 ETDRS letters in the left eye by the end of the loading phase | 2026-05-07 | completed | Left eye improved from 55 to 69 letters after three injections | S |
| Dry macula on OCT (central subfield thickness below 300 um, no fluid) by the end of the loading phase | 2026-05-07 | completed | Central subfield thickness fell from 418 to 274 um with no fluid | S |
| Check the Amsler grid daily for each eye and report any change the same day | 2026-07-02 | completed | Daily checks recorded; no new change in the right eye | S |
| Complete a low-vision rehabilitation evaluation and set up studio lighting and magnification by the July visit | 2026-07-02 | completed | Task lighting, a stand magnifier, and high-contrast labels in place; still painting daily | S |